Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy

Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy. We de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation (New York, N.Y.) N.Y.), 2003-07, Vol.108 (2), p.198-204
Hauptverfasser: SENNLAUB, F, VALAMANESH, F, GEBOES, K, VARMA, D. R, LACHAPELLE, P, ONG, H, BEHAR-COHEN, F, CHEMTOB, S, VAZQUEZ-TELLO, A, EL-ASRAR, A. M, CHECCHIN, D, BRAULT, S, GOBEIL, F, BEAUCHAMP, M. H, MWAIKAMBO, B, COURTOIS, Y
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy. We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36. These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.
ISSN:0009-7322
1524-4539
DOI:10.1161/01.cir.0000080735.93327.00